Target eGFR for Kidney Function: What Your Number Means

A note on terminology before anything else: this article is about kidney function eGFR, the lab value your primary care or telehealth clinician orders alongside a basic metabolic panel. It is unrelated to EGFR, the epidermal growth factor receptor gene sometimes tested in lung tumor tissue for cancer treatment selection. If you arrived here looking for cancer biomarker testing, this is not that page.

The direct answer

eGFR is a calculated estimate of kidney filtration derived from a routine blood creatinine level plus age and sex, not a direct measurement of true glomerular filtration rate. Current U.S. laboratory practice increasingly uses the 2021 CKD-EPI creatinine equation, which removed a race coefficient present in earlier formulas. A single eGFR reading below 60 mL/min/1.73 m² does not diagnose chronic kidney disease by itself; established clinical practice requires a second low reading at least 90 days later plus evaluation of urine albumin before a CKD stage is assigned, because dehydration, NSAID use, or acute illness can transiently lower eGFR without any chronic kidney damage.

What eGFR is measuring, and what it can't measure directly

True glomerular filtration rate is the volume of blood plasma the kidneys clear of a marker substance per minute, normalized to a standard body surface area. Measuring it directly requires an infused tracer such as iohexol or inulin, which is impractical for routine care. Instead, labs estimate it from serum creatinine, a muscle metabolism byproduct, combined with age and sex in a validated equation.

This estimation has known blind spots. Someone with unusually high muscle mass, or who takes creatine supplements, will generate more creatinine and can appear to have a lower eGFR than their true kidney function warrants. Someone with low muscle mass, common in older or frail patients, can have a falsely reassuring eGFR. When this ambiguity matters clinically, some labs and specialists add a cystatin C-based equation, since cystatin C production is less dependent on muscle mass. Whether cystatin C testing is warranted in a specific case is a judgment call for the ordering clinician, not something to decide from a single lab report.

The CKD stages, and why a low number alone isn't a diagnosis

Kidney function is commonly staged from G1 (normal or high, ≥90) through G5 (kidney failure, below 15), with intermediate stages G2, G3a, G3b, and G4 corresponding to progressively lower eGFR bands. This staging framework comes from KDIGO (Kidney Disease: Improving Global Outcomes), an international guideline body; the exact numeric cutoffs and any recent revisions should be checked against KDIGO's current published guideline rather than assumed from memory, since guideline documents are periodically updated.

Two features of the staging system matter more than the raw number:

Stage G1 or G2 alone is not CKD. KDIGO's framework requires evidence of kidney damage, albuminuria, a structural abnormality on imaging, or a pathologic finding, in addition to eGFR in the near-normal range. An eGFR of 65 with no proteinuria and a normal kidney ultrasound does not meet CKD criteria on eGFR alone.

Albuminuria is a co-classifier, not an afterthought. KDIGO pairs eGFR with urine albumin-to-creatinine ratio (UACR) categories to estimate progression risk. An eGFR of 55 with significant albuminuria carries meaningfully higher risk than the same eGFR with a normal UACR. A lab report showing eGFR without a paired UACR gives an incomplete picture, and clinicians managing CKD or diabetes typically order both together.

Why age changes what "normal" looks like

Measured GFR declines with age even in healthy people. Reference data generally place average GFR in healthy young adults well above 100 mL/min/1.73 m², with a gradual decline through older adulthood. The practical implication: an eGFR in the 60s in a person in their 70s, with no albuminuria and normal kidney imaging, may reflect ordinary aging rather than disease, while the same number in a 30-year-old is more likely to represent a real reduction in kidney reserve and deserves closer follow-up.

Trend matters more than any single value. A decline of roughly 5 mL/min/1.73 m² or more per year is generally treated as a warning sign that warrants closer monitoring or nephrology input, even if the absolute eGFR is still above 60. A person whose eGFR fell from 90 to 72 over a year and a half has a more concerning trajectory than someone stable at 58 for years, even though the second number is lower in absolute terms.

What a low eGFR usually means

The two leading causes of chronic kidney function decline in the United States are diabetic kidney disease and hypertension-related kidney damage; glomerulonephritis, polycystic kidney disease, lupus nephritis, and obstructive causes account for a smaller share. Reversible, acute causes of a low eGFR reading include dehydration, NSAID use, certain blood pressure medications in the setting of renal artery narrowing, contrast dye exposure, and rhabdomyolysis. This is exactly why a single low result triggers retesting rather than an immediate CKD label.

Most people with an eGFR between roughly 30 and 60 have no symptoms. Fatigue, fluid retention, reduced urine output, nausea, and difficulty concentrating tend to appear only once eGFR drops well below 30, which is why professional diabetes and kidney guidelines recommend routine, scheduled eGFR and urine albumin testing for at-risk patients rather than waiting for symptoms.

Reduced kidney function is also an independent cardiovascular risk marker in observational and trial data, meaning cardiovascular risk factors (blood pressure, lipids, glucose) generally need active management alongside kidney-specific care rather than in isolation. Specific trial-level numbers on cardiovascular risk reduction in CKD populations exist in the literature, but citing an exact percentage here would require verification against the primary trial publication rather than a secondhand summary, so no specific figure is stated.

What a high eGFR means

An eGFR above 90 with no albuminuria or structural abnormality is simply normal kidney function, not a finding requiring action. Values persistently above roughly 120 mL/min/1.73 m² can reflect hyperfiltration, a state in which the kidneys are filtering at an elevated rate that can mask early injury and, over time in some patients (notably early diabetes or obesity), precede a later decline. A high eGFR in someone with diabetes or obesity is worth tracking over time rather than treated as reassuring on its own.

Pregnancy substantially raises true GFR due to increased cardiac output and renal plasma flow, so an elevated eGFR in pregnancy can be physiologic. Standard eGFR equations are not validated for pregnancy, and clinicians use different tools and clinical judgment in that setting.

How eGFR changes medication decisions

This is the part of the lab report that most directly changes what a clinician will prescribe or continue. None of the following is a substitute for an individualized prescribing decision, it explains the general logic so a lab result makes sense.

Metformin. Metformin is renally cleared, and the concern is not direct kidney toxicity but accumulation that raises the risk of lactic acidosis when clearance is impaired. Current FDA labeling and ADA guidance generally describe metformin as usable without restriction at higher eGFR, usable with added caution and monitoring in an intermediate range, and contraindicated once eGFR falls below roughly 30. Because label language and exact cutoffs can be revised, anyone making a metformin continuation decision around a borderline eGFR should confirm the current label rather than rely on a remembered threshold.

GLP-1 receptor agonists (semaglutide, tirzepatide, and related agents). These are FDA-approved for type 2 diabetes and, in some formulations, chronic weight management; their renal handling differs from small-molecule drugs like metformin, and current labeling for at least some agents in this class does not require dose adjustment across a wide eGFR range. A large randomized cardiovascular/kidney outcomes trial in patients with type 2 diabetes and CKD reported a reduction in major kidney disease events with semaglutide compared to placebo; the exact effect size is a specific trial statistic that should be verified against the original trial publication before being quoted to a patient, since secondhand summaries of trial results are a common source of citation error. What is reasonably well supported is the general direction: this drug class is not automatically avoided in CKD and in some guideline frameworks is treated as a preferred option in patients who have both type 2 diabetes and reduced kidney function, though the specific guideline language should be confirmed against the current published algorithm rather than quoted verbatim without the source document in hand.

SGLT2 inhibitors. This class requires a minimum eGFR for its glucose-lowering effect (specific cutoffs vary by drug), but trial evidence has also shown kidney-protective effects extending into lower eGFR ranges than the glycemic-benefit cutoff. As with GLP-1 data above, exact trial numbers should be pulled from the primary trial report rather than restated from memory.

Testosterone replacement therapy. Testosterone itself is not typically dose-adjusted for eGFR, but it can raise hematocrit (erythrocytosis), and elevated blood viscosity can affect renal perfusion in someone who already has reduced kidney function. Checking hematocrit and eGFR on a shared schedule is reasonable practice for patients on TRT, though the exact interval is a clinical judgment call rather than a fixed rule.

NSAIDs and imaging contrast. Regular NSAID use is generally discouraged once eGFR is below 60 because of added acute kidney injury risk. Iodinated CT contrast requires a risk-benefit discussion at lower eGFR, and gadolinium-based MRI contrast has its own separate renal safety considerations. These are decisions for the ordering clinician and radiologist, not something to self-manage from a lab value.

What can and can't change the number

Plausibly modifiable, with caveats. Blood pressure control, glucose control in diabetes, reduction of proteinuria (including through RAAS-blocking medications), smoking cessation, and weight loss in patients with obesity-related hyperfiltration are all associated with slower kidney function decline in guideline literature and trial evidence. The strength of evidence varies by intervention, and exact magnitude-of-benefit numbers (for example, a specific percentage reduction in progression risk from a specific trial) should be verified against the primary source before being presented to a patient as a firm figure.

Not supported by good evidence. "Kidney cleanse" supplements, high-dose vitamin C, and non-prescribed bicarbonate loading do not have rigorous trial support for improving eGFR. Bicarbonate supplementation has a specific, narrower evidence base in CKD patients with measured low serum bicarbonate, which is a different clinical scenario from routine kidney health maintenance.

Artifacts, not true change. Creatine supplementation and very high protein intake raise creatinine production without changing true filtration, which can make calculated eGFR look worse than it is. If either applies, mention it to the ordering clinician before drawing conclusions from the number, and consider that stopping creatine for a couple of weeks before testing may give a more representative reading.

When to involve a nephrologist

Referral to kidney specialty care is generally appropriate for an eGFR below roughly 30, a rate of decline near or above 5 mL/min/1.73 m² per year, heavily elevated albuminuria, unexplained blood and protein in the urine together, blood pressure that remains uncontrolled on multiple medications, or any suspicion of a non-diabetic, non-hypertensive kidney disease. Most earlier-stage CKD is reasonably managed in primary care or telehealth settings with periodic labs; the threshold for specialist involvement is a clinical judgment that should be made by the treating clinician based on the full picture, not the eGFR number in isolation.

Reading your actual lab report

Most U.S. labs have moved to the 2021 CKD-EPI creatinine equation; some older reports may still reflect an earlier formula (MDRD), which is known to be less accurate at higher eGFR values. If a report is unclear about which equation was used, it is reasonable to ask the lab or clinician.

Many labs report results as "eGFR >60" or ">90" rather than a precise number, because equation precision is lower at higher filtration rates. That is reassuring as a category but does not distinguish a 62 from a 105, which matters if you are trying to track a trend over several years. If trend-tracking matters to your situation, ask whether the uncapped numeric value can be reported.

Evidence boundary: what is established, what isn't

Established: eGFR is a validated, guideline-endorsed estimate of kidney function used to stage CKD and to make medication safety decisions; a single low reading requires confirmation before diagnosis; albuminuria adds independent prognostic information beyond eGFR alone; metformin carries a recognized renal safety cutoff.

Plausible but requiring current-source verification: specific numeric benefits attributed to individual drugs or trials (exact percentage risk reductions, exact eGFR cutoffs for specific drug labels, exact guideline wording preferring one drug class over another). These claims are directionally consistent with what has been published in major trials and guidelines, but the precise figures in this article's source material could not be independently confirmed against the primary trial or label documents and should be checked before being used in patient-facing or clinical decision content.

Not established from the material available here: that any specific supplement, hydration regimen, or over-the-counter intervention meaningfully raises eGFR in a person with confirmed CKD.

Decision framework: what an eGFR number should actually trigger

This framework is a reasoning aid for interpreting a result you already have. It is not a substitute for an individualized clinical evaluation, and none of the "actions" below are dosing instructions.

A note on the sources behind this page

Automated evidence discovery for this topic returned papers about EGFR gene mutation testing in lung cancer, an entirely different subject that happens to share the abbreviation with kidney-function eGFR. None of those papers were used here because they do not support any claim about kidney filtration, CKD staging, or drug dosing by renal function. Several numeric claims common in secondary summaries of this topic (specific trial effect sizes, specific guideline quotations, specific drug label cutoffs) require direct verification against the primary trial publication, the current FDA label, or the current KDIGO and ADA guideline documents before they are presented as settled facts. Where this article states a specific number with confidence, it reflects information that is broadly consistent across standard kidney disease references; where a number could not be confirmed against a primary source in this review, the article says so rather than presenting an unverified figure as fact.

When to seek urgent care

Very low urine output, significant swelling, confusion, shortness of breath, or chest pain in someone with known reduced kidney function warrants urgent medical evaluation rather than waiting for a routine follow-up lab. A single lab report, including this one, cannot substitute for that judgment.